Compare EOG Resources Inc (EOG) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EOG Resources Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? EOG Resources Inc trades at $148.51 (market cap $77.90B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B). The key difference: Vertex Pharmaceuticals Incorporated is the larger of the two by market cap, and EOG Resources Inc pays a 2.75% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold EOG Resources Inc for 59 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| EOG | VRTX | |
|---|---|---|
Market Cap | $77.90B | $128.16B |
Volume | 2,930,386 | 806,603 |
Sector | Energy | Health |
52-Week High | $153.74 | $557.96 |
52-Week Low | $101.78 | $407.37 |
Typical Hold Time | 59 Days | 120 Days |
Enterprise Value | $81.24B | $122.29B |
Dividend Yield | 2.75% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EOG Resources trades at $144.21, down 0.05% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $164.77 implying 14% upside. The company has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $5.07 exceeding expectations, while maintaining strong profitability with a 25.81% net income margin and 22.51% ROE. Recent news highlights operational strength and disciplined capital allocation, with upcoming Q3 2026 results scheduled for November 6, 2026.
EOG presents a compelling value opportunity with attractive valuation multiples (P/E of 11.22, EV/EBITDA of 5.68) and strong shareholder returns through dividends. Key risks include oil price volatility, as seen in recent sector pullbacks, and execution of growth targets amid macroeconomic uncertainty. The absence of sell ratings from analysts and institutional accumulation support a positive medium-term outlook, though investors should monitor energy market dynamics and quarterly results.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% on the day, with a bearish technical signal despite a neutral oscillator reading. The company reported strong 2025 revenue of $12.00B and net income of $3.95B, with a net margin of 35%. Recent positive Phase 2b data for its kidney disease drug inaxaplin highlights pipeline expansion beyond cystic fibrosis dominance. Analyst consensus is strongly bullish with an 83.9% buy rating and a $573.50 price target, implying 13.4% upside.
The outlook for VRTX is positive, driven by its profitable core business and promising pipeline, but faces risks from clinical trial outcomes and competitive pressures. The stock's current valuation at a P/E of 29.45 is reasonable given its growth prospects, though investors should monitor execution on new drug approvals and market adoption.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About EOG Resources Inc
EOG Resources is an oil and gas producer with acreage in several U.S. shale plays, including the Permian Basin, the Eagle Ford, and the Bakken. At the end of 2021, it reported net proved reserves of 3.7 billion barrels of oil equivalent. Net production averaged 829 thousand barrels of oil equivalent per day in 2021 at a ratio of 72% oil and natural gas liquids and 28% natural gas.
Read more on EOG →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
